about
Low-dose "metronomic chemotherapy" with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit.Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer.Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer.Presence and distribution of growth factors in breast cyst fluid.Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer.Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement.Socioeconomic status and survival of gastric cancer patients.Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience.Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer.Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma.Fulvestrant for advanced male breast cancer patients: a case series.Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancerRole of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease“Burned out” phenomenon of the testis in retroperitoneal seminomaTopoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancerPrimary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2–T4 breast cancerEffect of fenretinide on bone mineral density and metabolism in women with early breast cancerEpidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breastThe metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancerPhase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end pointPresence of immunoassayable transforming growth factor-beta 1 (TGF-beta 1) in breast cyst fluid (BCF): relationship with the intracystic electrolyte and epidermal-growth-factor (EGF) contentLong-term effects of fenretinide on retinal functionHormonal Therapy and ChemopreventionCorrelation between plasma transforming growth factor-beta 1 and second primary breast cancer in a chemoprevention trialFulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centreHER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17
P50
Q36359098-B4CE157F-6339-4142-A364-0EBCE7C3BDAEQ36368120-9223DF37-5D8B-48D4-9C62-2D368DD4B860Q36977587-40C43ECA-B8C0-4207-B95D-CFEF12B30809Q40817904-1F85A485-2A13-4F18-BE09-E42BECA9E1B6Q40831744-130CC08A-31AD-4A51-B714-447C1DA07AB1Q40999459-C85E993E-1A24-48DC-9B3A-718D27D17B7CQ42781340-E5254B0F-44C8-4D45-AEE8-9EB0B0D65D30Q43062601-99958B01-A07C-4EC7-9BAB-864E2D61C37CQ43120755-CAC19720-34AD-4B10-B24D-D2056D7F3B19Q43209147-BC558877-EA94-49B5-98D6-04CE222854C6Q44407131-56C6723A-DEFB-4D75-8518-9E4A8BC41E83Q45953263-6E52C794-244B-44F9-B110-C6149C429F33Q46138991-2D47CE77-143F-47E2-80A1-84C1F18F778AQ46328432-3E6C9A30-7BC0-4E4C-B4FC-480D4AE27E25Q46365348-398D7E26-47BD-4113-AC39-573FF1A84037Q46862276-B23A7E32-74BE-4810-8707-6FA9536806CAQ46911956-F2979EF2-38A7-4DAB-9C9C-1AED459C93A7Q47390449-FB23A1F8-6366-4094-8AA8-D51A2A525F07Q50869613-E6C1FF35-2D73-4B9C-AF52-9E578979ADF4Q51019986-887E8FD6-649F-47BF-9DF5-A289ACFAC10FQ51733625-40241892-FDF6-475E-88E3-AADB0463E002Q51907341-0ED7EECC-023F-42C6-8E39-D44587EF56FBQ53527585-C1AEEE64-55A9-453E-A817-8A52670EB64FQ54600310-C6D6311C-7343-4F0D-AB25-56EDC54B7412Q56779235-72AFE575-A90E-4528-8418-25D3DFA632E2Q56779524-E931DCC6-BE9C-48CB-B051-95F671BF748CQ57580830-523E1B5E-481B-4550-BF8A-9018453774ACQ59489512-6E03E809-C73A-4225-B68F-39D6CB488899Q61948767-442C0E65-8D15-4BD0-B968-7513B00F0566Q61948775-AD97B64E-5402-4079-83F4-A22AE5A10B05Q72234086-096AF20D-8448-426A-9E14-936E4CAF4A1DQ72326609-9FBD89B8-5925-46E6-8776-89A95D1ECC39Q72606795-0F01BBF8-C809-4A86-AC06-9805F13E1E87Q72682240-9453A933-CE3B-4224-8FF4-FF88096244E8Q72878255-14E7A58E-9598-487D-A9A9-847AD5E911FEQ73158655-3C0424B5-7963-472A-B8A0-D588CE72E7C9Q73869443-279A451B-EAB1-4005-BAC7-C5F91A29DD1CQ77668100-2076AF31-29C7-4351-904C-9092AB24A38CQ79680651-59DBD3B9-2AA9-4F4E-B93C-A83B580532FBQ81249654-41F9A1C3-4B7A-4CB2-ADB6-A7212ED90FC1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rosalba Torrisi
@ast
Rosalba Torrisi
@en
Rosalba Torrisi
@es
Rosalba Torrisi
@nl
type
label
Rosalba Torrisi
@ast
Rosalba Torrisi
@en
Rosalba Torrisi
@es
Rosalba Torrisi
@nl
prefLabel
Rosalba Torrisi
@ast
Rosalba Torrisi
@en
Rosalba Torrisi
@es
Rosalba Torrisi
@nl
P106
P1153
6603808831
P31
P496
0000-0001-8344-6849